Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitor

Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitor

Abstract Respiratory syncytial virus (RSV) is a common cause of acute lower respiratory tract infection in infants, older adults and the immunocompromised. Effective directly acting antivirals are not yet available for clinical use. To address this, we screen the ReFRAME drug-repurposing library con...

Full description

Bibliographic Details
Main Authors: Svenja M. Sake, Xiaoyu Zhang, Manoj Kumar Rajak, Melanie Urbanek-Quaing, Arnaud Carpentier, Antonia P. Gunesch, Christina Grethe, Alina Matthaei, Jessica Rückert, Marie Galloux, Thibaut Larcher, Ronan Le Goffic, Fortune Hontonnou, Arnab K. Chatterjee, Kristen Johnson, Kaycie Morwood, Katharina Rox, Walid A. M. Elgaher, Jiabin Huang, Martin Wetzke, Gesine Hansen, Nicole Fischer, Jean-Francois Eléouët, Marie-Anne Rameix-Welti, Anna K. H. Hirsch, Elisabeth Herold, Martin Empting, Chris Lauber, Thomas F. Schulz, Thomas Krey, Sibylle Haid, Thomas Pietschmann
Format: Article
Language:English
Published: Nature Portfolio 2024-02-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-024-45241-y

Internet

https://doi.org/10.1038/s41467-024-45241-y

Similar Items